PL3601268T3 - Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu - Google Patents

Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu

Info

Publication number
PL3601268T3
PL3601268T3 PL18718340T PL18718340T PL3601268T3 PL 3601268 T3 PL3601268 T3 PL 3601268T3 PL 18718340 T PL18718340 T PL 18718340T PL 18718340 T PL18718340 T PL 18718340T PL 3601268 T3 PL3601268 T3 PL 3601268T3
Authority
PL
Poland
Prior art keywords
methyl
cyclopropaneamido
triazol
pyridazine
carboxamide
Prior art date
Application number
PL18718340T
Other languages
English (en)
Inventor
Ke Chen
Joerg Deerberg
Dong Lin
Michael DUMMELDINGER
Bahar INANKUR
Sergei V. Kolotuchin
Jun Li
Amanda J. ROGERS
Victor W. Rosso
Eric M. SIMMONS
Maxime C. D. SOUMEILLANT
Daniel S. Treitler
Jianji Wang
Bin Zheng
Michael J. Smith
Neil A. Strotman
Steven Tymonko
Tamas BENKOVICS
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3601268T3 publication Critical patent/PL3601268T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02—Preparation of hydrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL18718340T 2017-03-30 2018-03-29 Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu PL3601268T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478789P 2017-03-30 2017-03-30
EP18718340.5A EP3601268B1 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
PCT/US2018/025100 WO2018183649A1 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
PL3601268T3 true PL3601268T3 (pl) 2021-07-05

Family

ID=62002470

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18718340T PL3601268T3 (pl) 2017-03-30 2018-03-29 Proces przygotowania 6-(cyklopropanoamido)-4-((2-metoksy-3-(1-metylo-1h-1,2,4-triazol-3-ylo)fenylo)amino)-n-(metylo-d3)pirydyno-3-karboksyamidu

Country Status (23)

Country Link
US (5) US10899745B2 (pl)
EP (4) EP3882237B1 (pl)
JP (5) JP7260481B2 (pl)
KR (2) KR20190133725A (pl)
CN (4) CN116813561A (pl)
AU (3) AU2018244451B2 (pl)
BR (2) BR112019020169A2 (pl)
CA (2) CA3058177A1 (pl)
CY (1) CY1124194T1 (pl)
DK (1) DK3601268T3 (pl)
EA (2) EA201992308A1 (pl)
ES (2) ES2864450T3 (pl)
HR (1) HRP20210764T1 (pl)
HU (1) HUE054886T2 (pl)
IL (3) IL269594B2 (pl)
LT (1) LT3601268T (pl)
MX (4) MX2019011092A (pl)
PL (1) PL3601268T3 (pl)
PT (1) PT3601268T (pl)
RS (1) RS61816B1 (pl)
SG (2) SG11201908947QA (pl)
SI (1) SI3601268T1 (pl)
WO (2) WO2018183656A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI605041B (zh) 2012-11-08 2017-11-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應之調節劑之經醯胺基取代雜環化合物
AU2018244451B2 (en) * 2017-03-30 2022-03-10 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
JP2021525734A (ja) * 2018-05-31 2021-09-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US20220235039A1 (en) * 2019-06-12 2022-07-28 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP2022548688A (ja) 2019-09-18 2022-11-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の徐放性剤形
WO2021129467A1 (zh) * 2019-12-27 2021-07-01 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
US20230159520A1 (en) * 2020-02-26 2023-05-25 Beigene, Ltd. Tyk-2 inhibitor
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262A (zh) * 2020-06-09 2021-12-10 江苏先声药业有限公司 哒嗪类化合物
WO2022017494A1 (zh) * 2020-07-24 2022-01-27 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
CA3192982A1 (en) 2020-09-18 2022-03-24 Umesh KESTUR Dosage forms for tyk2 inhibitors comprising swellable cores
CN116615200A (zh) * 2020-10-20 2023-08-18 杭州领业医药科技有限公司 哒嗪衍生物的晶型
WO2022165141A1 (en) 2021-01-29 2022-08-04 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
WO2022212181A1 (en) 2021-03-29 2022-10-06 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4337655A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240050380A (ko) 2021-08-20 2024-04-18 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의결정 형태
IL311624A (en) * 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
WO2023076515A1 (en) 2021-10-28 2023-05-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
WO2023102085A1 (en) 2021-12-01 2023-06-08 Teva Czech Industries S.R.O. Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
US20230296250A1 (en) * 2022-03-21 2023-09-21 General Electric Company Turbine engine combustor and combustor liner
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
WO2024017150A1 (zh) * 2022-07-18 2024-01-25 苏州鹏旭医药科技有限公司 一种氘可来昔替尼的合成方法
WO2024088282A1 (zh) * 2022-10-28 2024-05-02 浙江华海药业股份有限公司 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237430T3 (es) * 1999-06-09 2005-08-01 Yamanouchi Pharmaceutical Co. Ltd. Nuevos derivados carboxamida heterociclicos.
AU2004311909A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as PPAR modulators for the treatment of diabetes
JP5114411B2 (ja) * 2005-09-29 2013-01-09 ビーエーエスエフ ソシエタス・ヨーロピア アルミノケイ酸塩と酸化アルミニウムを含有する成形体ならびにメチルアミンの連続的製法
CN101663279A (zh) * 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
BR112012006956A2 (pt) * 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
JP5816635B2 (ja) * 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013091011A1 (en) * 2011-12-21 2013-06-27 Biota Europe Ltd Heterocyclic urea compounds
MX352928B (es) * 2012-01-10 2017-12-13 Hoffmann La Roche Compuestos de piridazina-amida.
WO2013171643A1 (en) 2012-05-14 2013-11-21 Piramal Enterprises Limited An improved process for preparation of irbesartan
TWI605041B (zh) * 2012-11-08 2017-11-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應之調節劑之經醯胺基取代雜環化合物
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
AU2018244451B2 (en) * 2017-03-30 2022-03-10 Bristol-Myers Squibb Company Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide
JP2021525734A (ja) * 2018-05-31 2021-09-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態

Also Published As

Publication number Publication date
WO2018183649A1 (en) 2018-10-04
JP7260481B2 (ja) 2023-04-18
CA3058209A1 (en) 2018-10-04
ES2970229T3 (es) 2024-05-27
LT3601268T (lt) 2021-05-25
US20210107897A1 (en) 2021-04-15
AU2018244916A1 (en) 2019-11-21
EA201992308A1 (ru) 2020-02-13
JP2022166011A (ja) 2022-11-01
JP2024037836A (ja) 2024-03-19
AU2018244451A1 (en) 2019-11-21
US20200109134A1 (en) 2020-04-09
AU2018244916B2 (en) 2021-11-18
US11649226B2 (en) 2023-05-16
EP3601268A1 (en) 2020-02-05
AU2018244451B2 (en) 2022-03-10
US20230271946A1 (en) 2023-08-31
MX2019011231A (es) 2019-11-18
CN110475774A (zh) 2019-11-19
AU2021261839A1 (en) 2021-12-02
SI3601268T1 (sl) 2021-07-30
US20210371404A1 (en) 2021-12-02
US20200239449A1 (en) 2020-07-30
EA201992300A1 (ru) 2020-02-20
KR20190133726A (ko) 2019-12-03
BR112019020163A2 (pt) 2020-04-22
IL269594B1 (en) 2023-10-01
JP2020512370A (ja) 2020-04-23
MX2022010495A (es) 2022-09-21
BR112019020169A2 (pt) 2020-04-22
CA3058177A1 (en) 2018-10-04
CN116354939A (zh) 2023-06-30
CY1124194T1 (el) 2022-05-27
IL269594B2 (en) 2024-02-01
PT3601268T (pt) 2021-04-13
JP7476370B2 (ja) 2024-04-30
IL269594A (en) 2019-11-28
IL269586B (en) 2022-08-01
US10899745B2 (en) 2021-01-26
IL305615A (en) 2023-11-01
JP2020512380A (ja) 2020-04-23
EP3601268B1 (en) 2021-03-17
CN116813561A (zh) 2023-09-29
DK3601268T3 (da) 2021-05-03
WO2018183656A1 (en) 2018-10-04
EP3882237A2 (en) 2021-09-22
SG11201908947QA (en) 2019-10-30
HRP20210764T1 (hr) 2021-07-09
IL269586A (en) 2019-11-28
JP2023052683A (ja) 2023-04-11
KR102642407B1 (ko) 2024-02-28
JP7457758B2 (ja) 2024-03-28
AU2021261839B2 (en) 2023-07-20
EP3882237B1 (en) 2023-12-20
SG11201909018VA (en) 2019-10-30
RS61816B1 (sr) 2021-06-30
EP3601270A1 (en) 2020-02-05
ES2864450T3 (es) 2021-10-13
CN110914260A (zh) 2020-03-24
JP7113023B2 (ja) 2022-08-04
EP4296258A3 (en) 2024-03-20
EP4296258A2 (en) 2023-12-27
MX2022010496A (es) 2022-09-21
HUE054886T2 (hu) 2021-10-28
CN110475774B (zh) 2023-06-02
MX2019011092A (es) 2020-01-20
KR20190133725A (ko) 2019-12-03
EP3882237A3 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
IL269586A (en) Process for preparing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-H1-1, 2, 4-triazol-3-yl)phenyl)amino)-N-(methyl-3D)pyridazine -3-carboxamide
IL274066A (en) Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
IL269599A (en) 11, 13- modified schistosoxins for pain treatment
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
EP3541794A4 (en) 4 - ((6- (2- (2,4-DIFLUOROPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE AND METHOD FOR THE PRODUCTION THEREOF
IL271852A (en) Solid powder supplements containing quercetin, a process for their preparation and their formulations
EP3541800A4 (en) PROCESSES FOR THE PREPARATION OF 4 - ((6- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-HYDROXY-3- (5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL) PROPYL ) PYRIDIN-3-YL) OXY) BENZONITRILE
EP3541795A4 (en) PROCESSES FOR THE PREPARATION OF 4 - ((6- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-HYDROXY-3 (5-MERCAPTO-1H-1,2,4-TRIAZOL-1-YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis